| Detailed information |
|---|
| CancerLivER ID | 2463 |
| Biomarker | CLU |
| Biomarker Name/Symbol (given in Publication) | clusterin (CLU) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potenial Diagnostic marker for metastatic HCC and validated on independent dataset |
| Experimental Condition | Primary and metastatic HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in metastatic HCC than primary HCC |
| Level of significance | p < 0.001 |
| Source | Cell line and Tissue |
| PMID | 16247463 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | cell death, tumor progression, and neurodegenerative disorders |
| Cohort | 104 pairs of primary HCCs and their matched metastases [1 cohort set: 60 pairs of primary and metastatic; 2nd cohort set: 44pairs of primary and metastatic]; primary HCC cell line (H2-P) and its matched metastatic cell line (H2-M) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Primary and metastatic HCC |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |